In the last trading session, 3.51 million shares of the Black Diamond Therapeutics Inc (NASDAQ:BDTX) were traded, and its beta was 2.78. Most recently the company’s share price was $1.68, and it changed around -$0.1 or -5.62% from the last close, which brings the market valuation of the company to $95.19M. BDTX currently trades at a discount to its 52-week high of $7.66, offering almost -355.95% off that amount. The share price’s 52-week low was $1.59, which indicates that the current value has risen by an impressive 5.36% since then. We note from Black Diamond Therapeutics Inc’s average daily trading volume that its 10-day average is 14.85 million shares, with the 3-month average coming to 3.12 million.
Black Diamond Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.14. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended BDTX as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Black Diamond Therapeutics Inc is expected to report earnings per share of -0.05 for the current quarter.
Black Diamond Therapeutics Inc (NASDAQ:BDTX) trade information
Instantly BDTX has showed a red trend with a performance of -5.62% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.7800 on recent trading dayincreased the stock’s daily price by 39.57%. The company’s shares are currently down -21.50% year-to-date, but still down -1.75% over the last five days. On the other hand, Black Diamond Therapeutics Inc (NASDAQ:BDTX) is -22.22% down in the 30-day period. We can see from the shorts that 7.41 million shares have been sold at a short interest cover period of 13.94 day(s).
The consensus price target as assigned by Wall Street analysts is $14, which translates to bulls needing to increase their stock price by 88.0% from its current value. Analyst projections state that BDTX is forecast to be at a low of $11 and a high of $20.
Black Diamond Therapeutics Inc (BDTX) estimates and forecasts
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 20M in revenue for the current quarter. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -5.22%. Black Diamond Therapeutics Inc earnings are expected to increase by 43.16% in 2025, but the outlook is negative -6.71% per year for the next five years.
Black Diamond Therapeutics Inc (NASDAQ:BDTX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.70% of Black Diamond Therapeutics Inc shares, and 97.51% of them are in the hands of institutional investors. The stock currently has a share float of 100.22%. Black Diamond Therapeutics Inc stock is held by 123.0 institutions, with T. ROWE PRICE INVESTMENT MANAGEMENT, INC. being the largest institutional investor. By 2024-06-30, it held 20.5751% of the shares, which is about 10.66 million shares worth $49.67 million.
BELLEVUE GROUP AG, with 16.4409% or 8.52 million shares worth $39.69 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
